[1] |
LI L, ZHANG T H, XIAO M L, et al. Brain macrophage senescence in glioma[J]. Semin Cancer Biol, 2024, 104-105:46-60. doi: 10.1016/j.semcancer.2024.07.005 |
[2] |
LIN H, LIU C X, HU A K, et al. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives[J]. J Hematol Oncol, 2024, 17(1):31. doi: 10.1186/s13045-024-01544-7 |
[3] |
WEN P Y, WELLER M, LEE E Q, et al. Glioblastoma in adults: a Society for Neuro-Oncology(SNO)and European Society of Neuro-Oncology(EANO)consensus review on current management and future directions[J]. Neuro Oncol, 2020, 22(8):1073-1113. doi: 10.1093/neuonc/noaa106 |
[4] |
ALVES A H, NUCCI M P, MAMANI J B, et al. The advances in glioblastoma on-a-chip for therapy approaches[J]. Cancers, 2022, 14(4):869. doi: 10.3390/cancers14040869 |
[5] |
MA C, PENG Y S, LI H T, et al. Organ-on-a-chip: a new paradigm for drug development[J]. Trends Pharmacol Sci, 2021, 42(2):119-133. doi: 10.1016/j.tips.2020.11.009 |
[6] |
SLIKA H, KARIMOV Z, ALIMONTI P, et al. Preclinical models and technologies in glioblastoma research: evolution, current state, and future avenues[J]. Int J Mol Sci, 2023, 24(22):16316. doi: 10.3390/ijms242216316 |
[7] |
AGOSTI E, ANTONIETTI S, IUS T, et al. Glioma stem cells as promoter of glioma progression: a systematic review of molecular pathways and targeted therapies[J]. Int J Mol Sci, 2024, 25(14):7979. doi: 10.3390/ijms25147979 |
[8] |
ORAIOPOULOU M E, TZAMALI E, PAPAMATHEAKIS J, et al. Phenocopying glioblastoma: a review[J]. IEEE Rev Biomed Eng, 2023, 16:456-471. doi: 10.1109/RBME.2021.3111744 |
[9] |
PASUPULETI V, VORA L, PRASAD R, et al. Glioblastoma preclinical models: strengths and weaknesses[J]. Biochim Biophys Acta Rev Cancer, 2024, 1879(1):189059. doi: 10.1016/j.bbcan.2023.189059 |
[10] |
JAYARAM M A, PHILLIPS J J. Role of the microenvironment in glioma pathogenesis[J]. Annu Rev Pathol, 2024, 19:181-201. doi: 10.1146/annurev-pathmechdis-051122-110348 |
[11] |
Kaur S, Kaur I, Rawal P, et al. Non-matrigel scaffolds for organoid cultures[J]. Cancer Lett, 2021, 504:58-66. doi: 10.1016/j.canlet.2021.01.025 |
[12] |
Lin L, Chung CK. PDMS Microfabrication and Design for Microfluidics and Sustainable Energy Application: Review [J]. Micromachines(Basel), 2021, 12(11)pii: mi12111350. |
[13] |
Slika H, Karimov Z, Alimonti P, et al. Preclinical Models and Technologies in Glioblastoma Research: Evolution, Current State, and Future Avenues[J]. International Journal of Molecular Sciences, 2023, 24:16316. doi: 10.3390/ijms242216316 |
[14] |
ZHAO M N, VAN STRATEN D, BROEKMAN M L D, et al. Nanocarrier-based drug combination therapy for glioblastoma[J]. Theranostics, 2020, 10(3):1355-1372. doi: 10.7150/thno.38147 |
[15] |
MA R C, TAPHOORN M J B, PLAHA P. Advances in the management of glioblastoma[J]. J Neurol Neurosurg Psychiatry, 2021, 92(10):1103-1111. doi: 10.1136/jnnp-2020-325334 |
[16] |
脑胶质瘤中西医结合临床诊疗专家共识(上海)[J]. 上海中医药大学学报, 2023, 37(05): 1-10. |
[17] |
陈紫莹, 赵晓平, 范小璇, 等. 中药治疗脑胶质瘤作用机制研究进展[J]. 环球中医药, 2024, 17(5):959-964. doi: 10.3969/j.issn.1674-1749.2024.05.039 |
[18] |
齐帆, 赵晓平, 范小璇, 等. 中医药调控肿瘤微环境治疗脑胶质瘤的研究进展[J]. 中国实验方剂学杂志, 2024, 30(16):303-314. |
[19] |
国家药典委员会. 中华人民共和国药典-一部: 2020年版[M]. 北京: 中国医药科技出版社, 2020: 122. |
[20] |
CHEN Q, RAHMAN K, WANG S J, et al. Scutellaria barbata: a review on chemical constituents, pharmacological activities and clinical applications[J]. Curr Pharm Des, 2020, 26(1):160-175. doi: 10.2174/1381612825666191216124310 |
[21] |
唐笛笛, 赵晓平, 范小璇, 等. 半枝莲抗胶质瘤微血管生成的研究进展[J]. 环球中医药, 2023, 16(8):1701-1706. doi: 10.3969/j.issn.1674-1749.2023.08.044 |
[22] |
韩春辉. 白花蛇舌草、半枝莲及其药对提取物对人胶质瘤细胞迁移侵袭的影响及作用机制研究[D]. 大连: 大连医科大学, 2019. |
[23] |
HE X Y, XIONG L L, XIA Q J, et al. C18H17NO6 and its combination with scutellarin suppress the proliferation and induce the apoptosis of human glioma cells via upregulation of fas-associated factor 1 expression[J]. Biomed Res Int, 2019, 2019:6821219. |
[24] |
HE X Y, XU Y, XIA Q J, et al. Combined scutellarin and C18H17NO6 imperils the survival of glioma: partly associated with the repression of PSEN1/PI3K-AKT signaling axis[J]. Front Oncol, 2021, 11:663262. doi: 10.3389/fonc.2021.663262 |